Last reviewed · How we verify
Filgrastim Injectable Product
Stimulates the production of white blood cells by binding to and activating the G-CSF receptor.
Stimulates the production of white blood cells by binding to and activating the G-CSF receptor. Used for Neutropenia, Febrile neutropenia.
At a glance
| Generic name | Filgrastim Injectable Product |
|---|---|
| Also known as | filgrastim |
| Sponsor | Recardio, Inc. |
| Drug class | G-CSF agonist |
| Target | G-CSF receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells, particularly neutrophils, by binding to and activating the G-CSF receptor.
Approved indications
- Neutropenia
- Febrile neutropenia
Common side effects
- Bone pain
- Headache
- Injection site reaction
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (PHASE1)
- Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML (PHASE1, PHASE2)
- Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (PHASE2)
- Embryonal Tumor With Multilayered Rosettes (PHASE2)
- Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder (PHASE1)
- Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse (PHASE1, PHASE2)
- Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Filgrastim Injectable Product CI brief — competitive landscape report
- Filgrastim Injectable Product updates RSS · CI watch RSS
- Recardio, Inc. portfolio CI